Angion Biomedica and Vifor Pharma announced that their Phase III trial on ANG-3777 for renal transplant patients did not meet the study’s primary and secondary endpoints.

Novavax Inc. said on Oct. 27 the company had completed the real-time submission of an application for the authorization of the Covid-19 vaccine candidate NVX-CoV2373 in the United Kingdom.

The U.S. Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee recommended emergency use authorization (EUA) for the Pfizer-BioNTech vaccine for children 5 through 11 years of age, with 17 members voting yes and one abstention.

Raytheon Technologies’ top boss warned on Oct. 26 that the U.S. aerospace and defense firm will lose ‘several thousand’ employees who refused to take Covid-19 vaccines, as the company prepares to meet the Biden administration’s Dec. 8 deadline for immunization.

Cortexyme Inc. said on Oct. 26 the company’s experimental oral pill failed to meet the main goals of improving cognitive and functional abilities in patients with mild-to-moderate Alzheimer’s disease in a study.

With companies like GlaxoSmithKline and bluebird bio moving closer to splitting their businesses into multiple entities, Novartis is reviewing the Swiss drugmaker’s Sandoz division to determine the best moves going forward to maximize value for shareholders.